Boca Raton, FL, July 27, 2022 (GLOBE NEWSWIRE) — Sensus Healthcare, Inc. (Nasdaq: SRTS)) is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, offering 10 Transdermal Injection Systems™ Announced that it has been sold to the Hair Enhancement Center (HEC). Expanding chain of Texas-based hair loss treatment centers. This system is used to non-invasively deliver U.SK Under Skin’s hair-healthy serum Skin Savers Hair™. U.SK Under Skin is a subsidiary of privately held EMS Pharma, Brazil’s largest pharmaceutical company, and a subsidiary of Grupo NC, one of Brazil’s largest conglomerates.
Sensus will deliver two systems in the third quarter of 2022 and the remaining systems in the fourth quarter.
“The combination of U.SK Under Skin’s Hair Health Serum with the state-of-the-art Sensus TransDermal Infusion System allows the serum to be painlessly and rapidly delivered deep into the hair follicle,” commented CEO Paul Herchman. I’m here. hair growth center. “HEC executives have more than 35 years of experience in introducing new medical technologies to the global medical market, but we rely on a clinical advisory board of leading physicians to ensure that we deliver We are evaluating and ultimately recommending techniques for inclusion in our hair growth products.
U.SK Under Skin USA Chief Executive Officer Andre Freund said: downtime. Combined with U.SK Under Skin’s targeted skin saver ampoules, physicians and beauty professionals can enhance their existing treatments with an affordable, easy-to-use treatment that enhances results and increases patient satisfaction. can be increased. The device sends a painless microcurrent through the skin, allowing the skin saver to penetrate water channels between cells without damaging the skin or solutions. TransDermal Infusion allows molecules of up to 2 million Daltons to penetrate the skin, increasing their bioavailability and allowing patients to immediately see a difference in treatment outcomes. ”
Sensus Healthcare Chairman and CEO Joe Sardano said: “We are pleased to support the growth of their future clinic with U.SK Under Skin’s TransDermal Infusion System to provide hair health serums. , is an important indicator because it affects approximately 50 million American men and 30 million American women with male or female pattern baldness.”
“Moreover, our system can painlessly administer a large number of drugs for various medical applications, such as hyperhidrosis and other cosmetic applications,” Sardano added. “Patients and their doctors can get a lot out of the application if we can make the procedure painless,” he continues Sardano.
About the transdermal injection system
The TransDermal Infusion System is FDA cleared for use on any part of the body currently treated with needle injections. This allows a wide variety of fillers and other injectables to be administered without pain or downtime. Faster than traditional iontophoresis, the Transdermal Infusion System enables the delivery of otherwise non-absorbable agents commonly used in cosmetic procedures, such as Botox®, hyaluronic acid, lidocaine and collagen.
About the hair growth center
Hair Enhancement Centers was founded on the premise that hair loss is a treatable medical condition. HEC believes that medically-directed clinical hair regrowth therapy and hair transplant surgery are the best-in-class, minimally invasive solutions and options for treating hair loss in men and women of all ages. Hair Enhancement Centers use only FDA-cleared devices and work with respected national and regional physicians to bring breakthrough treatments to their patients. A new line of medical-grade hair growth products branded as Get Hair™ is designed to enhance the results of laser and transdermal injection treatments.
Hair Enhancement Centers expanded from one in Southlake, Texas a year ago to nine, and continues to expand to serve patients in Dallas/Fort. A worthy metroplex. For more information, please visit: www.hec-usa.com
About U.SK Underskin
U.SK Under Skin is a premium dermocosmetics brand that combines science and efficacy with sophistication and luxury. Founded in 2015, Under Skin brings a new concept to the dermocosmetics market. It’s the science behind beauty. Our products are characterized by Skin Care High Performance and have been developed under the guidance of the most renowned dermatologists, along with the expertise of Monteresearch®, an Italian research and development laboratory based in Milan. Under Skin combines innovative solutions for all skin types with the latest scientific discoveries to ensure the most effective, proven products.
Under Skin’s mission is to introduce innovative, high-performance products and technologies to dermatologists through international science and design, providing consumers with luxurious sensory experiences that enhance health, beauty and lifestyle. am. Owned by Brazilian company Grupo NC, Under Skin is part of EMS Pharma, one of the world’s largest pharmaceutical companies. For more information, see: www.underskin.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that specializes in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncology and non-oncology conditions. Sensus has developed a proprietary low-energy X-ray known as superficial radiation therapy (SRT), the culmination of over a decade of research and development, to treat non-melanoma skin cancers and keloids using the SRT-100. We provide technology.™SRT-100+™ and SRT-100 Vision™ system. It has a portfolio of innovative medical device products, including cosmetic lasers and needle-free transdermal injection systems.™, Sensus provides innovative treatment options that improve the quality of life for patients around the world. For more information, see: www.sensushealthcare.com.
Forward-Looking Statements
This press release contains statements that are or may be deemed to be “forward-looking statements.” Occasionally, these statements “believe,” “estimate,” “anticipate, expect, plan, intend, could, could, could , could, could, should, or the negative or other variations or equivalent terms of those terms, provided that all forward-looking statements include such terms It does not mean.
Forward-looking statements involve risks and uncertainties. This is because it relates to events, developments and circumstances related to Sensus, our industry and/or general economic or other circumstances. Or more or less than expected. Although we believe that the forward-looking statements contained in this press release are reasonably based, forward-looking statements are not based on our future performance, our actual results of operations, our It does not guarantee the development of the industry. The continuation and severity of the COVID-19 pandemic. This includes the impact on sales and marketing. our ability to achieve profitability; our ability to obtain and maintain the intellectual property necessary to adequately protect our products and our ability to infringe or avoid infringing the intellectual property rights of third parties; The level and availability of government and/or third party payer reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines. Regulatory requirements that apply to us and our competitors. Our ability to efficiently manage manufacturing processes and costs. risks arising from our international operations; Laws, regulations or other governmental actions affecting our products, taxes, international trade regulations or any other aspect of our business. Our concentration of customers in the United States and China, including the concentration of sales to certain customers in the United States. and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.
Furthermore, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictions of future results or developments. Any forward-looking statements we make in this press release speak only as of the date of such statements, and we make no such forward-looking statements to reflect events or circumstances after the date of this press release. We undertake no obligation to update any statements. Applicable law. To better understand the risks and uncertainties inherent in our business, we refer to our Preface to Forward-Looking Information and the Risk Factors section of our periodic reports filed with the Securities and Exchange Commission. Please read the listed factors carefully.
contact:
LHA Investor Relations
Kim Sutton Gorodets
212-838-3777
kgolodetz@lhai.com
# # #
